These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36096240)

  • 21. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics.
    Tasneem S; Alam MM; Amir M; Akhter M; Parvez S; Verma G; Nainwal LM; Equbal A; Anwer T; Shaquiquzzaman M
    Mini Rev Med Chem; 2022; 22(12):1648-1706. PubMed ID: 34939540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker.
    Yang F; Zhao N; Hu Y; Jiang CS; Zhang H
    Chem Biodivers; 2020 Jan; 17(1):e1900427. PubMed ID: 31793143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging approaches for histone deacetylase inhibitor drug discovery.
    Zwergel C; Valente S; Jacob C; Mai A
    Expert Opin Drug Discov; 2015 Jun; 10(6):599-613. PubMed ID: 25895649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
    Ru J; Wang Y; Li Z; Wang J; Ren C; Zhang J
    Eur J Med Chem; 2023 Dec; 261():115800. PubMed ID: 37708798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective Inhibitors of Histone Deacetylase 10 (HDAC-10).
    Pojani E; Barlocco D
    Curr Med Chem; 2022; 29(13):2306-2321. PubMed ID: 34468295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors].
    Harada T
    Rinsho Ketsueki; 2019; 60(9):1265-1274. PubMed ID: 31597852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Explorative study on isoform-selective histone deacetylase inhibitors.
    Suzuki T
    Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):897-906. PubMed ID: 19721249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives.
    Su M; Gong X; Liu F
    Expert Opin Drug Discov; 2021 Jul; 16(7):745-761. PubMed ID: 33530771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
    Beumer JH; Tawbi H
    Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
    Thaler F; Mercurio C
    ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of classification models for identification of important structural features of isoform-selective histone deacetylase inhibitors (class I).
    Neiband MS; Benvidi A; Mani-Varnosfaderani A
    Mol Divers; 2020 Nov; 24(4):1077-1094. PubMed ID: 31773377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.